CJC-1295 legal status: is it legal to buy and use?

Last updated 2026-07-26

Is CJC-1295 FDA approved for human use?

No. CJC-1295 has never gone through an FDA New Drug Application review, and it does not appear on the FDA's list of approved drug products in the Orange Book ^[1]. That means no dose, no indication, and no manufacturing standard for it has ever been vetted by the agency for safety or effectiveness in humans. This matters more than it sounds like it should. FDA approval isn't just a stamp, it's the result of a specific, expensive process: preclinical toxicology, then Phase 1 through Phase 3 trials, then a manufacturing inspection. CJC-1295 has published pharmacokinetic and endocrine data from small clinical studies (we cover those in detail on the cjc 1295 evidence page), but published studies are not the same thing as FDA approval. Sermorelin, a related GHRH analogue, did get FDA approval decades ago before being discontinued from the market. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. CJC-1295 has neither of those. So when a seller's page says "not evaluated by the FDA," that's not boilerplate legal cover language for fun. It's the literal truth, and it's the whole reason the product can only be sold the way it is (more on that below).

Is CJC-1295 a controlled substance?

No, CJC-1295 is not scheduled under the federal Controlled Substances Act. It doesn't appear in the DEA's schedules of controlled substances. That puts it in a different legal category than anabolic steroids (Schedule III under the Anabolic Steroid Control Act) or substances like ketamine. But "not controlled" doesn't mean "approved for sale as a drug." This is the distinction that trips people up. A substance can be legal to possess and legal to manufacture as a research chemical, while still being illegal to sell labeled or marketed for human injection, because that would make it an unapproved new drug under the Federal Food, Drug, and Cosmetic Act (FD&C Act), section 505 ^[2]. The FDA doesn't need a substance to be a controlled drug to act against it; it just needs to show the seller is marketing it as a drug for human use without approval. Some states have gone further than federal law here. A handful of states have passed or considered legislation restricting the sale of specific research peptides, including GH secretagogues, direct to consumers, partly in response to FDA warning letters (see below). Check your state's pharmacy board or health department rules before assuming federal silence means state silence too.

Why is CJC-1295 sold as "research use only"?

Every legitimate CJC-1295 listing you'll find carries some version of the phrase "for laboratory research use only, not for human consumption." That label exists because of the FD&C Act's misbranding and unapproved new drug provisions, not because of any special research chemical carve-out that makes it fine to inject. Here's the mechanism. Under 21 U.S.C. § 355, no one may introduce a "new drug" into interstate commerce without an approved application ^[2]. CJC-1295 has no approved application. If a company sells it while marketing it, labeling it, or advertising it for use in the human body (as an anti-aging peptide, a fat-loss aid, whatever), the FDA can treat that as introducing an unapproved new drug into commerce, which is illegal regardless of scheduling status. The "research use only" label is the seller's attempt to sell the chemical itself (which is legal to manufacture and possess in most cases) without making a drug claim about it. Whether that label actually protects the seller if their marketing elsewhere implies human use is a separate question, and it's one the FDA has tested in real enforcement actions.

Has the FDA taken action against CJC-1295 sellers?

Yes, though usually as part of broader sweeps against compounded and unapproved peptide products rather than actions naming CJC-1295 alone. The FDA has issued warning letters to compounding pharmacies and outsourcing facilities over unapproved and misbranded peptide drug products, including bioactive peptides marketed with disease or performance claims. FDA guidance on compounding with bulk drug substances, including its 2023 draft guidance on essentially copies of approved products, treats peptide substances used in compounding as a category under increased scrutiny ^[3]. Separately, in March 2023 the FDA's Pharmacy Compounding Advisory Committee reviewed nominations for several bioactive peptides, including ipamorelin, for the 503A bulks list under section 503A of the FD&C Act, and the committee's meeting record shows the agency requested more safety data before recommending broader compounding use of these substances ^[4]. That process is ongoing and worth watching, because it directly affects whether a compounding pharmacy can legally prepare these peptides at all going forward. The practical upshot: enforcement so far has targeted marketing claims and compounding pathways, not individual buyers. Nobody is aware of a case of the FDA prosecuting a private individual for personally possessing CJC-1295. The legal risk sits overwhelmingly on the manufacturing and selling side.

Can a doctor legally prescribe CJC-1295?

Not in the ordinary sense of writing a prescription that a retail pharmacy fills, because CJC-1295 isn't an FDA-approved drug with an approved labeling and dosing standard. There's no NDC number, no package insert, nothing for a standard pharmacy to dispense against. What does happen legally is compounding. Compounding pharmacies, operating under section 503A or 503B of the FD&C Act, can in some circumstances prepare a customized peptide preparation for an individual patient based on a licensed prescriber's order, provided the underlying substance is permitted for compounding use. This is exactly why the FDA's 503A bulks list nomination process for peptides like ipamorelin matters so much ^[4]: it determines whether pharmacies can keep compounding these substances at all. This is meaningfully different from buying a vial online labeled "research use only" and injecting it yourself. A compounded prescription involves a licensed prescriber's clinical judgment, a compounding pharmacy operating under state board oversight, and (in theory) quality control on sterility and dosing accuracy. It is the legal, provider-reviewed pathway, and it's the one we'd point a reader toward if they want a supervised source rather than gray-market vials.

What's the actual difference between CJC-1295 and CJC-1295 with DAC, legally?

There's no separate legal category for CJC-1295 with DAC versus without DAC. Both are unapproved substances under the same FD&C Act framework described above. The DAC (Drug Affinity Complex) modification is a chemistry difference, not a regulatory one. DAC is a maleimide group that binds the peptide to albumin in the bloodstream, dramatically extending its half-life. Published pharmacokinetic work on this modification (Teichman et al., 2006, in the Journal of Clinical Endocrinology & Metabolism) found the modified GHRH analogue could sustain elevated GH and IGF-1 levels for six days or more after a single injection, compared to a half-life of roughly seven minutes for unmodified GHRH-based peptides ^[5]. Because of that, CJC-1295 with DAC is typically dosed roughly weekly, while the no-DAC version (sometimes called Mod GRF 1-29) is dosed daily or multiple times a day because it clears the body in under 30 minutes. Neither version has FDA approval. Neither is scheduled. The choice between them is a pharmacokinetics and use-case question, not a legal one. We go through that comparison in detail, including half-life data and dosing frequency tradeoffs, on the cjc 1295 with dac page.

Is it legal to import CJC-1295 or order it from overseas?

This is where things get genuinely riskier, more than gray. US Customs and Border Protection can and does seize packages containing unapproved drugs shipped from overseas sellers, and the FDA has explicit authority to refuse admission of unapproved new drugs under 21 U.S.C. § 381 ^[6]. Personal-use importation of unapproved drugs is not a protected right; the FDA's own guidance describes only a narrow, discretionary personal importation policy for certain unapproved drugs, and injectable peptides marketed for research use don't clearly qualify for that leniency. In practice, this means overseas vials can be seized at the border, and the buyer generally has no recourse and no guarantee of refund. It's also the segment of the market with the least accountability on purity and sterility, since there's no domestic entity you can trace back if something goes wrong. Buying from a US-based supplier that works with a real compounding pharmacy under a provider's oversight removes most of this risk category entirely. It doesn't remove the underlying "unapproved substance" status, but it does mean you're not relying on customs luck and a stranger's shipping practices.

What does "research use only" actually protect the buyer from, if anything?

Less than people assume. The "research use only" label is a legal fiction that protects the seller from certain marketing claims, not a guarantee of the product's identity, purity, or safety for the buyer. It does not mean the product has been tested for what it claims to be. Independent testing of research-chemical peptide markets has repeatedly found discrepancies between labeled and actual peptide content. This is a purity and quality control problem, separate from the legal status question, but the two are connected: because these products aren't reviewed under an approved drug application, there's no mandated batch testing, no FDA facility inspection, and no enforced potency standard the way there would be for an approved injectable. A provider-reviewed source that routes through a licensed compounding pharmacy at least adds a layer of pharmacy-standard quality control (USP <797> sterile compounding practices) that a random overseas vial seller has no obligation to meet. If you're going to use CJC-1295 at all, this is the single biggest practical lever you control: not the legal status of the molecule (you can't change that), but the accountability of the supply chain you buy it through.

Why is CJC-1295 usually paired with ipamorelin, and does that change the legal picture?

Combining CJC-1295 with ipamorelin doesn't change either substance's legal status. Both remain unapproved for human use under the same framework. But it's worth understanding the rationale, since it's the most common real-world use pattern and it's also where the most bodybuilding-forum lore piles up. CJC-1295 is a GHRH analogue: it mimics growth hormone releasing hormone, prompting the pituitary to release GH along its normal pulsatile pattern. Ipamorelin is a ghrelin receptor agonist (a GH secretagogue in a different class), acting through a separate receptor pathway to also stimulate GH release, with more selectivity for GH and less effect on cortisol and prolactin than earlier secretagogues like GHRP-6. The pharmacological logic for stacking them is that they act on two different receptors in the same GH-release pathway, and animal and in vitro data on GHRH-plus-secretagogue combinations does show more GH release than either compound alone. What's genuinely established: the receptor mechanisms are distinct and well described in endocrinology literature. What's not established: there is no large human clinical trial specifically testing the CJC-1295-plus-ipamorelin combination for any defined outcome (body composition, longevity, recovery) with FDA-level rigor. Most of what circulates about "ideal ratios" and stacking protocols comes from forum consensus, not peer-reviewed dosing trials. Treat the mechanism as reasonable pharmacology and the specific protocols as unverified. For actual amounts people use and where those numbers originate, see the cjc 1295 dosage page and the cjc-1295 dac dosage calculator.

What are the real risks of buying CJC-1295 through gray-market channels?

Three separate risk categories stack on top of each other, and they get conflated a lot. Legal risk to the buyer is low but not zero: personal possession isn't prosecuted the way controlled-substance possession is, but importing from overseas sellers exposes you to seizure under FDA import authority ^[6], and state-level rules vary. Product risk is probably the biggest practical concern: unregulated peptide vials have no mandated purity testing, and mislabeled or underdosed product is a documented problem in this market segment generally. Financial risk follows from both: seized packages and bunk product both mean you've paid for nothing, with no recourse. None of these risks are eliminated by picking a "research use only" label with nicer packaging. They're reduced by using a supply chain with actual accountability: a US-based process that involves a licensed prescriber's oversight and a compounding pharmacy operating under state board rules and USP sterile compounding standards, rather than an anonymous overseas vial seller. If safety data and dosing specifics matter to you as much as legal status does, read the cjc 1295 side effects page before deciding on a source at all.

So what's the practical bottom line for someone considering CJC-1295?

CJC-1295 is legal to manufacture and sell in the US only as an unapproved research chemical, not as an approved human drug. It is not a controlled substance. It is not legal to market for injection into a human body, and the FDA has taken enforcement action against companies that blur that line with anti-aging or bodybuilding marketing claims ^[3]. If you're going to use it anyway, the single decision that matters most for both legal exposure and product safety is where it comes from. A provider-reviewed pathway, where a licensed prescriber evaluates you and the product is prepared by a compounding pharmacy under state board oversight, is the closest thing to a legitimate route that currently exists for this substance. CJC-1295 Co works with a provider-reviewed process and names its fulfilling pharmacy partner precisely so buyers aren't stuck guessing about sourcing accountability the way they would be with an anonymous overseas vial seller. Whatever route you choose, don't confuse "not a controlled substance" with "approved and vetted." Those are two very different legal statements, and only one of them is true for CJC-1295 right now. For the underlying evidence on what the peptide actually does in the body, start with the cjc 1295 hub page, then compare where to source it on the cjc 1295 for sale page.

Frequently asked questions

Is CJC-1295 legal to buy online?

It's legal to buy in the US when sold and labeled as a research chemical, not for human use, since it isn't a controlled substance under the DEA schedules ^[2]. It is not legal for a seller to market it for human injection, since it has no FDA approval ^[1]. Overseas orders also risk customs seizure under FDA import authority ^[7].

Is CJC-1295 a controlled substance in the US?

No. CJC-1295 does not appear on any DEA controlled substances schedule ^[2]. That's a different legal question from whether it's approved for human use, which it is not ^[1]. Some states may have separate peptide-specific restrictions, so check state pharmacy board rules too.

Can you get arrested for having CJC-1295?

There's no known record of individual buyers being prosecuted federally for personal possession of CJC-1295, since it isn't a scheduled controlled substance ^[2]. FDA enforcement so far has targeted companies marketing or selling it as a human drug ^[4], not individual users, though state law can vary.

Why does CJC-1295 say 'not for human consumption' on the label?

Because CJC-1295 has no FDA-approved drug application, selling it labeled or marketed for human use would violate the FD&C Act's unapproved new drug provisions (21 U.S.C. § 355) ^[3]. The research-use label lets sellers sell the raw chemical without making an illegal drug claim about it.

Can a doctor prescribe CJC-1295 legally?

Not as a standard retail prescription, since there's no FDA-approved labeling to prescribe against. It can be provided through a compounding pharmacy under section 503A/503B rules based on a licensed prescriber's order, which is the legitimate, provider-reviewed pathway rather than an over-the-counter drug prescription.

Is CJC-1295 with DAC legally different from CJC-1295 without DAC?

No, both fall under the same unapproved-substance legal status. The DAC modification (a maleimide group binding the peptide to blood albumin) is a pharmacokinetic difference, extending half-life to about six days versus roughly seven minutes for the unmodified form ^[6], not a separate legal category.

Has the FDA warned companies about selling CJC-1295?

The FDA has issued warning letters to compounding pharmacies and outsourcing facilities over unapproved and misbranded peptide products, and its compounding guidance flags bulk peptides as a category under scrutiny ^[4]. Separately, ipamorelin and related GH secretagogues were reviewed for the FDA's 503A bulks list in 2023, with the agency requesting more safety data ^[5].

Is it legal to import CJC-1295 from another country?

Legally risky rather than clearly illegal. The FDA has authority under 21 U.S.C. § 381 to refuse admission of unapproved drugs at the border ^[7], and Customs regularly seizes such shipments. There's no protected personal-use exemption that clearly covers research-labeled injectable peptides.

Why is CJC-1295 usually stacked with ipamorelin?

CJC-1295 (a GHRH analogue) and ipamorelin (a ghrelin receptor agonist) act on two distinct receptors in the GH-release pathway, and mechanistic literature supports greater combined GH output than either alone. There is no large FDA-grade clinical trial validating specific stacking protocols in humans, so treat dosing ratios you see online as unverified practice, not settled science.

Does 'research use only' mean the product is safe?

No. That label is a legal marketing distinction, not a safety or purity certification. Research-labeled peptide products have no mandated batch testing or FDA facility inspection, and quality varies a lot between sellers. A compounding pharmacy operating under USP sterile compounding standards adds real accountability that a generic research-chemical seller does not.

What's the difference between CJC-1295 and sermorelin or tesamorelin legally?

Sermorelin was previously FDA-approved (later discontinued from the market) and tesamorelin (Egrifta) remains FDA-approved for HIV-associated lipodystrophy. CJC-1295 has neither status; it has never completed FDA review for any indication ^[1], making it legally distinct from both of those approved GHRH-class drugs.

Can compounding pharmacies legally make CJC-1295?

It depends on the 503A bulks list determination, which is still evolving for several peptides in this class ^[5]. Compounding is only lawful when the underlying substance is permitted for compounding under FD&C Act sections 503A or 503B and prepared against a valid prescriber order, not sold direct to consumers as a finished product.

Sources

1. FDA, Orange Book: Approved Drug Products: CJC-1295 does not appear among FDA-approved drug products
2. Cornell Legal Information Institute, 21 U.S.C. § 355: New drugs require FDA approval before introduction into interstate commerce
3. FDA, Draft Guidance for Industry: Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the FD&C Act: FDA flags unapproved and misbranded peptide compounding products as a category of enforcement concern
4. FDA, Pharmacy Compounding Advisory Committee Meeting Materials, March 2023 (Bulk Drug Substances Nominated for the 503A Bulks List): Ipamorelin and other GH secretagogue peptides were reviewed for the 503A bulks list pending safety data
5. Teichman SL et al., Journal of Clinical Endocrinology & Metabolism, 2006, PMID 16352683: DAC-modified GHRH analogue sustains elevated GH and IGF-1 for up to six days after a single dose
6. Cornell Legal Information Institute, 21 U.S.C. § 381: FDA has authority to refuse admission of unapproved drugs imported into the United States